News summaryThe Motley FoolNov 14, 2026, 04:12 PM
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
In the 12 months ended September 30, 2026, Axsome Therapeutics generated about $865.3 million in revenue, approximately 54% higher than in the prior period. [[fact-d86izuc14]] Axsome reported a net loss of around $157.3 million over that period. [[fact-b7k7bi2es]] Moderna generated about $2.5 billion in revenue in the 12 months ended September 30, 2026, growing approximately 13.7% over the prior period. [[fact-us2dnf34c]] Moderna recorded a net loss of around $2.8 billion over that period. [[fact-ith9wk6ky]] The article's author considers Axsome the better buy for 2027, citing Moderna's premium valuation and Axsome's revenue growth. [[fact-5htr1lyal]]